Despite the many obstacles that remain, it is clear why Big Pharma is stepping up – and continuing – its efforts in the emerging markets. By 2015, sales in these countries are expected to account for 28% of global pharmaceuticals spending, while the US and Europe are set to continue to shrink.

See on social.eyeforpharma.com